ArticleActa diabetologica2026
Impact of national continuous glucose monitoring reimbursement on utilization and glycemic outcomes in children and adolescents with type 1 diabetes.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous glucose monitoring (CGM) use is associated with improved glycaemic outcomes and reduced hypoglycaemia in type 1 diabetes; however, access remains limited due to cost and reimbursement disparities.
methodsThis retrospective observational study included children and adolescents with type 1 diabetes followed in a single center. Clinical outcomes before and after reimbursement were compared using paired statistical analyses.
resultsThe implementation of the reimbursement policy in Türkiye was associated with improved access to diabetes technology through reduced financial barriers and with favourable changes in clinical outcomes. CGM usage increased significantly from 26% (n = 11) before reimbursement to 92% (n = 38) after reimbursement. A slight reduction in mean HbA1c levels was observed (from 9.08% to 8.99%). In children under 10 years of age, the proportion achieving target HbA1c levels (< 7%) increased from 16% to 33% (p = 0.042). In addition, a decreasing trend in hypoglycemia frequency and emergency department visits was observed following continuous glucose monitoring use.
conclusionThe introduction of a national reimbursement policy was associated with a marked increase in access to CGM in children and adolescents with type 1 diabetes. However, changes in glycaemic outcomes were limited and not statistically significant in the overall cohort. These findings suggest that the primary impact of reimbursement was improved adoption of diabetes technology rather than substantial short-term improvement in glycaemic control. Further large-scale studies are needed to evaluate long-term clinical outcomes and patient-reported benefits.
Indexed as
Identifiers
42455340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.